Literature DB >> 1352245

Is xamoterol safe in chronic airflow obstruction?

J A Roberts1, V F Challenor, D G Waller.   

Abstract

We have demonstrated in a group of 10 patients with CAO that treatment with xamoterol (200 mg b.i.d. for 7 days) did not alter lung function or respiratory symptoms. These results suggest that xamoterol can be used to treat mild heart failure in patients with CAO.

Entities:  

Mesh：

Substances：

Year:  1992        PMID： 1352245     DOI： 10.1007/bf00278474

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN： 0031-6970            Impact factor:   2.953


  13 in total

1.  A critical review of the systolic time intervals.

Authors:  R P Lewis; S E Rittogers; W F Froester; H Boudoulas
Journal:  Circulation       Date:  1977-08       Impact factor: 29.690

2.  Clinical efficacy of xamoterol, a beta 1-adrenoceptor partial agonist, in mild to moderate heart failure. U.K. Xamoterol Study Group.

Authors:  D G Waller; J Webster; C A Sykes; K K Bhalla; R Wray
Journal:  Eur Heart J       Date:  1989-11       Impact factor: 29.983

3.  Dose-response curves to inhaled beta-adrenoceptor agonists in normal and asthmatic subjects.

Authors:  P J Barnes; N B Pride
Journal:  Br J Clin Pharmacol       Date:  1983-06       Impact factor: 4.335

4.  Provocative dose and dose-response curve to inhaled propranolol in asthmatic patients with bronchial hyperresponsiveness to methacholine.

Authors:  A Foresi; A Chetta; G M Corbo; A Cuomo; D Olivieri
Journal:  Chest       Date:  1987-09       Impact factor: 9.410

5.  Effects of xamoterol (ICI 118,587) in asthmatic patients.

Authors:  C G Löfdahl; N Svedmyr
Journal:  Br J Clin Pharmacol       Date:  1984-10       Impact factor: 4.335

6.  Adverse effect of propranolol on airway function in nonasthmatic chronic obstructive lung disease.

Authors:  E H Chester; H J Schwartz; G M Fleming
Journal:  Chest       Date:  1981-05       Impact factor: 9.410

7.  Double-blind placebo-controlled comparison of digoxin and xamoterol in chronic heart failure. The German and Austrian Xamoterol Study Group.

Authors: 
Journal:  Lancet       Date:  1988-03-05       Impact factor: 79.321

8.  Beta-adrenoceptor blockers and terbutaline in patients with chronic obstructive lung disease. Effects and interaction after oral administration.

Authors:  J Wunderlich; H N Macha; H Wudicke; H Huckauf
Journal:  Chest       Date:  1980-11       Impact factor: 9.410

9.  A comparative study on the ventilatory and haemodynamic effects of xamoterol and atenolol in asthmatic patients.

Authors:  J W Lammers; M E Müller; H T Folgering; C L van Herwaarden
Journal:  Br J Clin Pharmacol       Date:  1986-11       Impact factor: 4.335

10.  A new method for measuring airway resistance in man using a body plethysmograph: values in normal subjects and in patients with respiratory disease.

Authors:  A B DUBOIS; S Y BOTELHO; J H COMROE
Journal:  J Clin Invest       Date:  1956-03       Impact factor: 14.808
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.